Advertisement

Clinical and Experimental Medicine

, Volume 19, Issue 4, pp 407–416 | Cite as

The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis

  • Yaoan Wen
  • Yeda Chen
  • Xiaolu Duan
  • Wei Zhu
  • Chao Cai
  • Tuo Deng
  • Guohua ZengEmail author
Review Article
  • 114 Downloads

Abstract

The prognostic value of programed death-ligand 1 (PD-L1) in urothelial carcinoma (UC) has been assessed in previous studies, while the results remain controversial and heterogeneous. Therefore, we performed this meta-analysis to explore the prognostic effect of PD-L1 in patients with UC. PubMed, Embase and Web of Science were searched to identify the studies. Hazard ratios (HR) with 95% confidence interval (95% CI) and clinicopathological factors were extracted from included studies. A total of 1819 patients with UC from 11 published studies were incorporated. The results of meta-analysis showed that positive PD-L1 expression was significantly associated with poorer overall survival (OS) (HR 1.59, 95% CI 1.05–2.40) and disease-free survival (DFS) (HR 1.83, 95% CI 1.03–3.25), but not recurrence-free survival. Moreover, in the subgroup analysis, significant associations between PD-L1 expression and OS or DFS were found in bladder UC, the cutoff value of positive expression of PD-L1 ≥ 5% and the expression of PD-L1 on the tumor cell membrane. Interestingly, positive PD-L1 expression was correlated with poorer pathological T stage (OR 2.03, 95% CI 1.46–2.82). Our meta-analysis implies that PD-L1 might be a valuable biomarker of poor prognosis for UC, especially bladder UC, although further large-scale and well-designed studies are warranted to verify the prognostic value of PD-L1 for UC.

Keywords

PD-L1 Urothelial carcinoma Prognosis Meta-analysis Biomarker 

Notes

Funding

This work was financed by grants from the National Natural Science Foundation of China (No. 81402430), the Collaborative Innovation Project of Guangzhou Education Bureau (No. 1201620011) and the Guangzhou Science Technology and Innovation Commission (No. 201704020193).

Compliance with ethical standards

Conflict of interest

All authors declare that they have no competing interests.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors. All the data involved in this study were extracted from published articles.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. CA: a cancer journal for clinicians. Cancer Stat. 2017;67(1):7–30.  https://doi.org/10.3322/caac.21387.CrossRefGoogle Scholar
  2. 2.
    Roupret M, Babjuk M, Comperat E, et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73(1):111–22.  https://doi.org/10.1016/j.eururo.2017.07.036.CrossRefGoogle Scholar
  3. 3.
    Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig. 2015;125(9):3384–91.  https://doi.org/10.1172/jci80011.CrossRefPubMedGoogle Scholar
  4. 4.
    Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol. 2017;8:1597.  https://doi.org/10.3389/fimmu.2017.01597.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB. Anti-Programmed cell death 1/ligand 1 (PD-1/PD-L1) antibodies for the treatment of urothelial carcinoma: state of the art and future development. Clin Genitourin Cancer. 2017.  https://doi.org/10.1016/j.clgc.2017.11.002.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Afreen S, Dermime S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. Hematol Oncol Stem Cell Ther. 2014;7(1):1–17.  https://doi.org/10.1016/j.hemonc.2013.09.005.CrossRefPubMedGoogle Scholar
  7. 7.
    Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4.  https://doi.org/10.1126/scitranslmed.aad7118.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34(11):556–63.  https://doi.org/10.1016/j.it.2013.07.003.CrossRefPubMedGoogle Scholar
  9. 9.
    Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17(8):1064–75.  https://doi.org/10.1093/neuonc/nou307.CrossRefPubMedGoogle Scholar
  10. 10.
    Riobello C, Vivanco B, Reda S, et al. Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer. Head Neck. 2018;40(4):818–27.  https://doi.org/10.1002/hed.25067.CrossRefPubMedGoogle Scholar
  11. 11.
    Cha YJ, Kim HR, Lee CY, Cho BC, Shim HS. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer. 2016;97:73–80.  https://doi.org/10.1016/j.lungcan.2016.05.001.CrossRefPubMedGoogle Scholar
  12. 12.
    Jiang D, Xu YY, Li F, Xu B, Zhang XG. The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism. Med Oncol. 2014;31(11):268.  https://doi.org/10.1007/s12032-014-0268-1.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhao LW, Li C, Zhang RL, et al. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem. 2014;116(7):1163–8.  https://doi.org/10.1016/j.acthis.2014.06.003.CrossRefPubMedGoogle Scholar
  14. 14.
    Boorjian SA, Sheinin Y, Crispen PL, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14(15):4800–8.  https://doi.org/10.1158/1078-0432.ccr-08-0731.CrossRefPubMedGoogle Scholar
  15. 15.
    Pichler R, Heidegger I, Fritz J, et al. PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. Oncotarget. 2017;8(40):66849–64.  https://doi.org/10.18632/oncotarget.19913.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22.  https://doi.org/10.1016/s1470-2045(17)30065-7.CrossRefPubMedGoogle Scholar
  17. 17.
    Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26(4):812–7.  https://doi.org/10.1093/annonc/mdv009.CrossRefPubMedGoogle Scholar
  18. 18.
    Erlmeier F, Seitz AK, Hatzichristodoulou G, et al. The role of PD-L1 expression and intratumoral lymphocytes in response to perioperative chemotherapy for urothelial carcinoma. Bladder Cancer. 2016;2(4):425–32.  https://doi.org/10.3233/blc-160067.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Krabbe LM, Heitplatz B, Preuss S, et al. Prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. J Urol. 2017;198(6):1253–62.  https://doi.org/10.1016/j.juro.2017.06.086.CrossRefPubMedGoogle Scholar
  20. 20.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.  https://doi.org/10.1016/j.ijsu.2010.02.007.CrossRefPubMedGoogle Scholar
  21. 21.
    Lan X, Zhang MM, Pu CL, et al. Impact of human leukocyte antigen mismatching on outcomes of liver transplantation: a meta-analysis. World J Gastroenterol. 2010;16(27):3457–64.CrossRefGoogle Scholar
  22. 22.
    Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev. 2012;8:Cd007814.  https://doi.org/10.1002/14651858.cd007814.pub2.CrossRefGoogle Scholar
  23. 23.
    Hogeveen M, Blom HJ, den Heijer M. Maternal homocysteine and small-for-gestational-age offspring: systematic review and meta-analysis. Am J Clin Nutr. 2012;95(1):130–6.  https://doi.org/10.3945/ajcn.111.016212.CrossRefPubMedGoogle Scholar
  24. 24.
    Xylinas E, Robinson BD, Kluth LA, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014;40(1):121–7.  https://doi.org/10.1016/j.ejso.2013.08.023.CrossRefPubMedGoogle Scholar
  25. 25.
    Necchi A, Lo Vullo S, Giannatempo P, et al. Association of androgen receptor expression on tumor cells and PD-L1 expression in muscle-invasive and metastatic urothelial carcinoma: insights for clinical research. Clin Genitourin Cancer. 2017.  https://doi.org/10.1016/j.clgc.2017.09.016.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Skala SL, Liu TY, Udager AM, Weizer AZ, Montgomery JS, Palapattu GS, et al. Programmed death-ligand 1 expression in upper tract urothelial carcinoma. Eur Urol Focus. 2017;3(4–5):502–9.  https://doi.org/10.1016/j.euf.2016.11.011.CrossRefPubMedGoogle Scholar
  27. 27.
    Wu CT, Chen WC, Chang YH, Lin WY, Chen MF. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep. 2016;6:19740.  https://doi.org/10.1038/srep19740.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Zhang B, Yu W, Feng X, et al. Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma. Med Oncol. 2017;34(5):94.  https://doi.org/10.1007/s12032-017-0941-2.CrossRefPubMedGoogle Scholar
  29. 29.
    Yaguchi T, Kawakami Y. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol. 2016;28(8):393–9.  https://doi.org/10.1093/intimm/dxw030.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Li X, Acuff NV, Peeks AR, et al. Tumor progression locus 2 (Tpl2) activates the mammalian target of rapamycin (mTOR) pathway, inhibits forkhead box P3 (FoxP3) expression, and limits regulatory T cell (Treg) immunosuppressive functions. J Biol Chem. 2016;291(32):16802–15.  https://doi.org/10.1074/jbc.M116.718783.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96(1):21–33.  https://doi.org/10.1111/imcb.1003.CrossRefPubMedGoogle Scholar
  32. 32.
    Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.CrossRefGoogle Scholar
  33. 33.
    Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.  https://doi.org/10.1146/annurev.immunol.26.021607.090331.CrossRefGoogle Scholar
  34. 34.
    Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol. 2018;71(3):189–94.  https://doi.org/10.1136/jclinpath-2017-204853.CrossRefPubMedGoogle Scholar
  35. 35.
    Wang Y, Wu L, Tian C, Zhang Y. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Ann Hematol. 2018;97(2):229–37.  https://doi.org/10.1007/s00277-017-3176-6.CrossRefPubMedGoogle Scholar
  36. 36.
    Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33:23–35.  https://doi.org/10.1016/j.coi.2015.01.006.CrossRefPubMedGoogle Scholar
  37. 37.
    Seifert AM, Zeng S, Zhang JQ, et al. PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2017;23(2):454–65.  https://doi.org/10.1158/1078-0432.ccr-16-1163.CrossRefPubMedGoogle Scholar
  38. 38.
    Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.  https://doi.org/10.1056/NEJMoa1613683.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Lavoie JM, Bidnur S, Black PC, Eigl BJ. Expanding immunotherapy options for bladder cancer: commentary on: pembrolizumab as second-line therapy for advanced urothelial carcinoma. Urology. 2017;106:1–2.  https://doi.org/10.1016/j.urology.2017.04.001.CrossRefPubMedGoogle Scholar
  40. 40.
    Hanna KS. A review of immune checkpoint inhibitors for the management of locally advanced or metastatic urothelial carcinoma. Pharmacotherapy. 2017;37(11):1391–405.  https://doi.org/10.1002/phar.2033.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Urology, Minimally Invasive Surgery CenterThe First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of UrologyGuangzhouChina

Personalised recommendations